Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, CP Hu, S Qin, G Cheng… - OncoTargets and …, 2018 - Taylor & Francis
Background The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT1523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …
被引用次数：9 相关文章

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.

S Lu, W Li, C Zhou, CP Hu, S Qin, G Cheng… - Oncotargets and …, 2018 - europepmc.org
Background The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT01523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, CP Hu, S Qin, G Cheng… - OncoTargets and …, 2018 - go.gale.com
Background: The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT01523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, CP Hu, S Qin, G Cheng… - OncoTargets and …, 2018 - dovepress.com
Background: The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT01523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, H Cheng-Ping, S Qin… - OncoTargets and …, 2018 - search.proquest.com
Background: The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT01523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …
[HTML] nih.gov

[HTML][HTML] Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, CP Hu, S Qin, G Cheng… - OncoTargets and …, 2018 - ncbi.nlm.nih.gov
Materials and methods We conducted a post hoc analysis of data for patients in LUX-Lung 8
from mainland China (n= 67). Compared with erlotinib, afatinib reduced the risk of disease …

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

S Lu, W Li, C Zhou, CP Hu, S Qin… - OncoTargets and …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT01523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.

S Lu, W Li, C Zhou, CP Hu, S Qin… - OncoTargets & …, 2018 - search.ebscohost.com
Abstract Background: The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov:
NCT01523587) identified significant improvements in progression-free survival (PFS) …